Neuroprotection of low dose carbon monoxide in Parkinson’s disease models commensurate with the reduced risk of Parkinson’s among smokers

Over several decades of research, smoking has consistently been associated with a reduced risk of Parkinson's disease (PD), raising the possibility that factors in cigarette smoke may confer protection. A team of scientists explored the neuroprotective potential of carbon monoxide in PD models.
Neuroprotection of low dose carbon monoxide in Parkinson’s disease models commensurate with the reduced risk of Parkinson’s among smokers
Like

Share this post

Choose a social network to share with, or copy the URL to share elsewhere

This is a representation of how your post may appear on social media. The actual post will vary between social networks

Key findings

  • Treatment with an oral formulation of CO at low dose comparable to that experienced by smokers protected against hallmark features of PD in animal models, including loss of dopamine cells and accumulation of α-synuclein pathology.
  • Low dose CO activated signaling cascades that limit oxidative stress and degrade α-synuclein, the protein that aggregates in neurons in PD.  
  • Heme oxygenase 1 (HO-1), a key protein in the oxidative stress response that was increased with CO exposure, was higher in the cerebrospinal fluid (CSF) of human smokers compared to nonsmokers. In PD brain samples, HO-1 levels were higher in neurons free from α-synuclein pathology.

Why is this important?

  • These findings suggest that molecular pathways activated by low dose CO may slow onset and limit pathology in PD. 
  • They support further investigation into low-dose CO and the pathways it modifies to slow disease progression in PD.
  • These observations suggest that CO may contribute to the reduced risk of PD among smokers.

What's next?

  • The research team is studying the pathways activated by low dose CO in experimental models to determine how they provide neuroprotection and to optimize their efficacy. 
  • Building on multiple Phase 1 and Phase 2 clinical studies in both healthy people and people with a variety of clinical conditions showing safety of CO at the low doses studied here, a clinical trial of low-dose, orally administered CO in PD patients is planned. 

Please sign in or register for FREE

If you are a registered user on Research Communities by Springer Nature, please sign in

Follow the Topic

Parkinson's disease
Life Sciences > Biological Sciences > Neuroscience > Neurological Disorders > Parkinson's disease
Parkinson's disease
Life Sciences > Biological Sciences > Neuroscience > Neurological Disorders > Movement Disorders > Parkinson's disease
Parkinson's disease
Life Sciences > Biological Sciences > Neuroscience > Neurological Disorders > Neurodegenerative diseases > Parkinson's disease
Parkinson's disease
Life Sciences > Health Sciences > Clinical Medicine > Neurology > Neurological Disorders > Parkinson's disease
Parkinson's disease
Life Sciences > Health Sciences > Clinical Medicine > Neurology > Neurological Disorders > Movement Disorders > Parkinson's disease
Parkinson's disease
Life Sciences > Health Sciences > Clinical Medicine > Neurology > Neurological Disorders > Neurodegenerative diseases > Parkinson's disease

Related Collections

With collections, you can get published faster and increase your visibility.

AI-assisted identification of novel multimodal imaging markers and underlying mechanisms in PD

This collection invites research papers on the application of AI in multimodal neuroimaging and related topics in Parkinson's disease and other related disorders.

Publishing Model: Open Access

Deadline: Jul 13, 2025

Parkinson’s Disease and the Microbiome

This collection invites research surrounding all aspects of the indigenous microbiome as it relates to Parkinson’s disease etiology, progression, and treatment.

Publishing Model: Open Access

Deadline: Jul 28, 2025